| pubmed-article:7484482 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7484482 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:7484482 | lifeskim:mentions | umls-concept:C0001792 | lld:lifeskim |
| pubmed-article:7484482 | lifeskim:mentions | umls-concept:C0024117 | lld:lifeskim |
| pubmed-article:7484482 | lifeskim:mentions | umls-concept:C0004048 | lld:lifeskim |
| pubmed-article:7484482 | lifeskim:mentions | umls-concept:C0015259 | lld:lifeskim |
| pubmed-article:7484482 | lifeskim:mentions | umls-concept:C0242896 | lld:lifeskim |
| pubmed-article:7484482 | lifeskim:mentions | umls-concept:C1516240 | lld:lifeskim |
| pubmed-article:7484482 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:7484482 | pubmed:dateCreated | 1995-12-8 | lld:pubmed |
| pubmed-article:7484482 | pubmed:abstractText | To test the effects of the inhaled anticholinergic drug, oxitropium bromide (OTB), on exercise capacity and dyspnoea in elderly patients (more than 75 years old) with chronic obstructive pulmonary disease (COPD), we performed cycle exercise testing on 12 elderly patients with COPD [mean age 78.7 (SD 1.1) years; FEV1% 41.3 (2.0)%] as well as 12 middle-aged COPD patients [mean age 60.1 (1.0) years; FEV1% 38.9 (2.4)%] before and after inhalation of OTB or placebo in a double-blind and placebo-controlled design. Spirometry was repeated immediately before and 30 min after OTB or placebo inhalation. Dyspnoea was quantitatively evaluated using the slope of the regression line between Borg scale and oxygen uptake (VO2) during exercise (Borg scale slope: BSS). After OTB inhalation, spirometric indices, exercise capacity as indexed by maximal VO2, and dyspnoea index (BSS) were improved compared with pre-inhalation value in both the elderly and middle-aged patients. The magnitude of improvements in these indices in the elderly patients was not different from that in the middle-aged. We conclude that the inhaled anticholinergic drug produces useful improvements in dyspnoea and exercise capacity in both elderly and middle-aged COPD patients. | lld:pubmed |
| pubmed-article:7484482 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7484482 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7484482 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7484482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7484482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7484482 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7484482 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7484482 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:7484482 | pubmed:issn | 0002-0729 | lld:pubmed |
| pubmed-article:7484482 | pubmed:author | pubmed-author:FukuchiYY | lld:pubmed |
| pubmed-article:7484482 | pubmed:author | pubmed-author:TeramotoSS | lld:pubmed |
| pubmed-article:7484482 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7484482 | pubmed:volume | 24 | lld:pubmed |
| pubmed-article:7484482 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7484482 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7484482 | pubmed:pagination | 278-82 | lld:pubmed |
| pubmed-article:7484482 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:7484482 | pubmed:meshHeading | pubmed-meshheading:7484482-... | lld:pubmed |
| pubmed-article:7484482 | pubmed:meshHeading | pubmed-meshheading:7484482-... | lld:pubmed |
| pubmed-article:7484482 | pubmed:meshHeading | pubmed-meshheading:7484482-... | lld:pubmed |
| pubmed-article:7484482 | pubmed:meshHeading | pubmed-meshheading:7484482-... | lld:pubmed |
| pubmed-article:7484482 | pubmed:meshHeading | pubmed-meshheading:7484482-... | lld:pubmed |
| pubmed-article:7484482 | pubmed:meshHeading | pubmed-meshheading:7484482-... | lld:pubmed |
| pubmed-article:7484482 | pubmed:meshHeading | pubmed-meshheading:7484482-... | lld:pubmed |
| pubmed-article:7484482 | pubmed:meshHeading | pubmed-meshheading:7484482-... | lld:pubmed |
| pubmed-article:7484482 | pubmed:meshHeading | pubmed-meshheading:7484482-... | lld:pubmed |
| pubmed-article:7484482 | pubmed:meshHeading | pubmed-meshheading:7484482-... | lld:pubmed |
| pubmed-article:7484482 | pubmed:meshHeading | pubmed-meshheading:7484482-... | lld:pubmed |
| pubmed-article:7484482 | pubmed:meshHeading | pubmed-meshheading:7484482-... | lld:pubmed |
| pubmed-article:7484482 | pubmed:meshHeading | pubmed-meshheading:7484482-... | lld:pubmed |
| pubmed-article:7484482 | pubmed:meshHeading | pubmed-meshheading:7484482-... | lld:pubmed |
| pubmed-article:7484482 | pubmed:meshHeading | pubmed-meshheading:7484482-... | lld:pubmed |
| pubmed-article:7484482 | pubmed:meshHeading | pubmed-meshheading:7484482-... | lld:pubmed |
| pubmed-article:7484482 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7484482 | pubmed:articleTitle | Improvements in exercise capacity and dyspnoea by inhaled anticholinergic drug in elderly patients with chronic obstructive pulmonary disease. | lld:pubmed |
| pubmed-article:7484482 | pubmed:affiliation | Department of Geriatrics, Faculty of Medicine, University of Tokyo, Japan. | lld:pubmed |
| pubmed-article:7484482 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7484482 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7484482 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7484482 | lld:pubmed |
